Novel Therapies for Advanced Urologic Cancers

Axel Heidenreich


Curr Opin Urol. 2020;30(4):594-601. 

In This Article

Abstract and Introduction


Purpose of review: Systemic treatment of advanced urogenital malignancies has changed significantly in recent years and it will continue to change rapidly in upcoming years. It is the scope of this review article to providing the reader with the most recently approved treatment strategies to be used in daily routine for the individualized and most optimal treatment of our patients.

Recent findings: Immunooncological therapy (IOT) has emerged as the treatment of choice in metastatic renal cell carcinoma and we describe the most relevant clinical trials and we will give some differential therapeutic recommendation who might be best treated with which combination therapy considering both oncological efficacy and treatment-related toxicity. New neoadjuvant treatment options for muscle-invasive bladder cancer are reported. With regard to metastatic prostate cancer, the landscape of medical therapy is continuously evolving and the new, and most relevant therapeutic strategies for metastatic hormone-naive and castration-resistant PCA are described. Last, but not least, we highlight latest developments in the management of advanced testis cancer.

Summary: The novel treatment options reported in this article are ready for use in daily routine and already represent or will shortly represent new guideline-recommended therapies.


The therapeutic options in locally advanced or metastatic urogenital cancers have changed dramatically during the last 5 years resulting in a significantly improved prognosis for most of our patients. Modern multimodality strategies in locally advanced disease have resulted in reduced systemic relapse rates and improved survival. New systemic therapies combining drugs with different modes of actions such as immuno-oncologic therapy in combination with cytotoxic medications or VEGFR-inhibitors have resulted in high objective response rates and significantly improved survival rates as compared with the standard therapeutic approaches.

It is the aim of the current article to provide subjective, concise reviews of novel therapies for advanced urogenital cancers highlighting the most important and interesting articles among the many published within the past 12 months that have direct impact on the clinical management of patients.